科華生物(002022.SZ)獲得中國合格評定國家認可委員會(CNAS)實驗室認可證書
格隆匯3月2日丨科華生物(002022.SZ)公佈，公司於近日收到中國合格評定國家認可委員會(“CNAS”)授予的實驗室認可證書(註冊號：CNASL13117),公司參考實驗室獲得了CNAS認可資格。CNAS證明公司參考實驗室符合ISO/IEC17025：2017《檢測和校準實驗室能力的通用要求》(CNAS-CL01《檢測和校準實驗室能力認可準則》)的要求，證書生效日期為2020年02月17日，有效期至2026年02月16日。此次參考實驗室認可項目包括丙氨酸氨基轉移酶(ALT)、天門冬氨酸氨基轉移酶(AST)、α-澱粉酶(AMY)、鹼性磷酸酶(ALP)、肌酸激酶(CK)、乳酸脱氫酶(LDH)、γ-谷氨酰基轉移酶(GGT)七個項目。
中國合格評定國家認可委員會(英文縮寫為：CNAS)是根據《中華人民共和國認證認可條例》的規定，由國家認證認可監督管理委員會(CNCA)批准設立並授權的國家認可機構，統一負責對認證機構、實驗室和檢驗機構等相關機構的認可工作。CNAS是國際認可論壇(IAF)、國際實驗室認可合作組織(ILAC)、亞太實驗室認可合作組織(APLAC)和太平洋認可合作組織(PAC)的正式成員(2019年1月1日起，PAC和APLAC合併成立新的區域認可合作組織“亞太認可合作組織”(APAC))，是國內最具權威性的實驗室認可管理機構。CNAS認可已經融入國際認可互認體系，在國際認可活動中佔據重要地位。
公司參考實驗室成立於2009年，從2010年開始每年參加國際臨牀化學和實驗室醫學聯合會(IFCC)組織的國際參考實驗室室間質評(RELA)，先後開發了酶類、代謝物和底物類、甲狀腺激素及類固醇激素類供15個項目的參考方法，並在IFCC-RELA活動中獲得優異成績。
公司此次獲得CNAS參考實驗室認可資格，標誌着公司參考實驗室測量能力及與之對應的質量管理體系獲得國際國內的權威認可，實驗室認可範圍內的測量結果實現全球互認，有助於提升公司品牌影響力和產品綜合競爭能力，但其對未來業績的貢獻程度尚不能預計。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
